Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PCI Biotech Holding ASA's Enterprise Value is kr36.17 Mil.
PCI Biotech Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-16.32 Mil. Therefore, PCI Biotech Holding ASA's EV-to-EBIT ratio for today is -2.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PCI Biotech Holding ASA's Enterprise Value
For the Biotechnology subindustry, PCI Biotech Holding ASA's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Enterprise Value distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's Enterprise Value falls into.
PCI Biotech Holding ASA Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
PCI Biotech Holding ASA's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA (OSL:PCIB) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
PCI Biotech Holding ASA's current Enterprise Value is kr36.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-16.32 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
PCI Biotech Holding ASA's EV-to-EBITDA for today is:
PCI Biotech Holding ASA's current Enterprise Value is kr36.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-16.02 Mil.
PCI Biotech Holding ASA's current Enterprise Value is kr36.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil.
PCI Biotech Holding ASA's current Enterprise Value is kr36.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-13.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA Enterprise Value Related Terms
Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSL:PCIB has been successfully added to your 